Analysis of the preventive effect of pegylated recombinant human granulocyte stimulating factor on granulocytopenia in metastatic hormone-sensitive prostate cancer after chemotherapy
10.3760/cma.j.cn311847-20200117-00032
- VernacularTitle:聚乙二醇化重组人粒细胞刺激因子对转移性激素敏感性前列腺癌化疗后粒细胞减少的预防效果分析
- Author:
Hong CHANG
1
;
Jie FANG
1
;
Huili XU
1
;
Jinzhuan ZHANG
1
;
Haibing DONG
1
Author Information
1. 201204 上海，上海安达医院肿瘤血液科
- Publication Type:Journal Article
- Keywords:
Granulocyte stimulating factor;
Prostatic cancer;
Docetaxel;
Neutropenia
- From:
Chinese journal of nautical medicine and hyperbaric medicine
2020;27(3):312-315
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the preventing effect of pegylated recombinant human granulocyte stimulating factor (PEG-rhG-CSF) on granulocytopenia after chemotherapy for prostate cancer, and to evaluate its safety and effectiveness.Methods:A total of 61 patients aged 53-82 with metastatic hormone-sensitive prostate cancer (mHSPC), who received docetaxel (75 mg/m 2, 21 days constitute one chemotherapy course) alone or docetaxel (75 mg/m 2 on d1) combined with cisplatin (30 mg/m 2, from d1 to d3) and carboplatin (400 mg/m 2, from d1 to d3) during a 21-day chemotherapy course from February 2019 to December 2019, were included. These patients also received endocrine therapy over the same period, including surgical and medical castration, and castration combined with antiandrogen medications, lasting 6 cycles in total. Patients were divided into two groups, the control group (30 cases) and the observation group (31 cases). The control group received no leukogenic drugs, and was given human granulocyte stimulating factor (rhG-CSF) treatment only after the occurrence of granulocytopenia until the WBC count in peripheral blood was above 10×10 9/L. The observation group was given PEG-rhG-CSF within 48 hours after chemotherapy. Results:Among the 61 patients, one patient died, two stopped receiving chemotherapy due to liver dysfunction, one was lost to follow-up. A total of 57 valid cases were included in per protocol set (PPS) in the end, of which 30 cases were from the observation group and 27 cases from the control group. The incidence of neutropenia in the observation group was 33.3%, of which the incidence of grade 3 neutropenia was 10.0%, the incidence of agranulocytosis was 0, and the drug doses reduction of chemotherapy was 0, which were lower than the 77.8%, 33.3%, 18.5%, and 18.5%, respectively, in the control group, with statistically significant differences ( P<0.05). The differences in adverse reactions in both groups, included aching bones, muscle pain, lack of strength, and soreness at the injection sites, were of no statistical significance ( P>0.05). Conclusion:The curative effect of PEG-rhG-CSF is definite on the patients with mHSPC who received chemotherapy either with docetaxel alone or docetaxel combined with cisplatin and carboplatin. It can reduce the incidence of granulocytopenia, agranulocytosis, and chemotherapy drug dose reduction caused by myelosuppression. It, therefore, can ensure the patients receive chemotherapy with standard dosage, and thus improve the cure rate.
